EXCLUSIVE: Botanical Synthesis Tech-Focused BioHarvest’s First Synthetic Olive Cells Shows Reduced Fat Accumulation in Liver Cells

On Tuesday, BioHarvest Sciences Inc. (NASDAQ:BHST) published ‘in vitro’ test results for its new olive cell compound, which can reduce fat accumulation in human liver cells.

BioHarvest demonstrated that its novel olive cell compound mitigated fat accumulation in human liver cells, both in a liver steatosis model and in experimental liver fibrosis models.

Also Read: EXCLUSIVE: BioHarvest Collaborates With Tate & Lyle To Develop Proprietary Plant-Based Molecules

The company attributes the reduction of fat accumulation in liver cells to the high levels …

Full story available on Benzinga.com